Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Trading Dashboard Log In Required
    • Trading Dashboard Log In Required
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Fidelity Alternative Investments Program Log In Required
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • Fidelity Rewards+registered trademark Log In Required
    • New Account Checklist Log In Required
    • Lending Solutions-Line of Credit Log In Required
    • Refer a Friend
  • Planning & Advice
    • What We Offer
    • Build Your Plan
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
    • Saving & Investing for a Child
  • News & Research
    • News
    • Wealth Management Insights
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Stocks and Trading
    • Direct Indexing
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sustainable Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Accounts
    • Annuities
    • Life Insurance & Long Term Care
    • Charitable Giving
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • Marketplace Solutions
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Virtual Assistant Opens in a new window
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments

BY Reuters
— 8:06 PM ET 01/24/2022

Jan 24 (Reuters) - The U.S. health regulator revised on Monday the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly (LLY) to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.

The Food and Drug Administration (FDA) said the treatments are currently not cleared for use in any U.S. states or territories, but may be authorized in certain regions if they work against potential new variants.

The agency highlighted other therapies that are expected to be effective against Omicron, including a rival antibody drug from GlaxoSmithKline and Vir Biotechnology (VIR) as well as recently authorized antiviral pills from Pfizer and Merck & Co. (MRK) (https://reut.rs/3FVKVHS)

Last month, the U.S. government had paused the distribution of Regeneron and Lilly's treatments and said the halt would continue until new data emerges on their efficacy against Omicron.

The highly contagious new variant was estimated to account for more than 99% of cases in the United States, as of Jan. 15.

GSK and Vir Biotech are boosting production of their drug, sotrovimab, to help meet soaring demand in the United States. The FDA has also expanded its approval for the use of Gilead Sciences' (GILD) antiviral COVID-19 drug remdesivir to treat non-hospitalized patients aged 12 years and above.

The Washington Post earlier in the day reported that the FDA was expected to revise authorizations for Regeneron and Lilly's treatments. Regeneron said it is working with the FDA to bring additional monoclonal antibody treatments to patients.

"Pending regulatory discussions, new therapeutic candidates could enter the clinic in coming months," the company said in a statement.

Lilly had no immediate comment but pointed to its statement from December saying its antibody candidate, bebtelovimab, maintains neutralization activity against all known variants of concern, including Omicron.

(Reporting by Amruta Khandekar and Ann Maria Shibu; Editing by Devika Syamnath and Sherry Jacob-Phillips)

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More MRK News

  • Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis
    GlobeNewswire - 8:00 AM ET 01/04/2022
Fidelity Investments. Copyright 1998–2022 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close